



Timothy J. LaBua

SENIOR COUNSEL

781 419-9652 direct

timothy.labua@faberlawgroup.com

Tim is highly adept at counseling emerging growth life science companies in connection with a variety of financing and strategic partnership challenges, as well as merger and acquisition transactions. He also has extensive experience representing publicly-traded companies and helping business development teams navigate the complexities of early-stage strategic investments and purchase options.

EXPERIENCE

Skadden, Arps, Slate, Meagher & Flom LLP

Associate Attorney

Wilmer Cutler Pickering Hale & Dorr LLP

Associate Attorney

- Investment & Operations Counsel at prominent value-focused hedge fund

RECENT CLIENT WORK

- GV in its purchase of preferred equity in Endcadia, Inc.
- Apic Bio, Inc. in its Series A Financing.
- XyloCor Therapeutics, Inc. in its Series A Financing.
- Venn Biosciences Corporation in its Series A Financing.
- Guardian Therapeutics, LLC in its acquisition of Band Therapeutics, LLC.
- Kantum Diagnostics, Inc. in its convertible debt financing.
- Synedgen, Inc. in its out-license of IP and sale of assets to Synspira, LLC
- Synspira, LLC in its equity/debt financing and research funding from The Cystic Fibrosis Foundation Trust
- Profit Tools, Inc. in its sale of certain assets to Valsoft Corporation.
- FOG Pharmaceuticals, Inc. in its Series B Financing.
- LifeMine Therapeutics, Inc. in its Series A Financing.
- Renoviso, Inc. in its Series A-1 Financing.
- Lundbeckfond Ventures in its sale of certain royalty rights.
- Bio-Pharm, Inc. in its acquisition by Torrent Pharmaceuticals Ltd.
- Hexcel Corporation in its acquisition of the aerospace and defense business of Oxford Performance Materials, Inc.

Bar Admissions

- Massachusetts

Education

- University of Michigan Law School, Dean's Scholarship
- Brown University, B.A.



Tim LaBua (continued)

- Alnylam Pharmaceuticals, Inc. in its strategic collaboration with Vir Biotechnology to develop RNAi therapeutics for infectious diseases.
- .406 Ventures, LLC in its purchase of preferred equity in Trilio Data, Inc.
- .406 Ventures, LLC as selling shareholder in the acquisition of Jisto, Inc. by Trilio Data, Inc.
- VivoPharm Pty. Ltd. in its acquisition by Cancer Genetics, Inc.
- GO Therapeutics, Inc. in its Series A-1 Financing.
- Lysosomal Therapeutics, Inc. in its exclusive option arrangement with Allergan plc.
- PTC Therapeutics, Inc. in its Senior Secured Term Loan Facility.
- Hexcel Corporation in its strategic investment in Carbon Conversions, Inc.